The NSDB leadership is staffed by a team of individuals whose collective backgrounds and expertise cover the broad multidisciplinary nature of cancer nanotechnology.
The mission of the Nanodelivery Systems and Devices Branch is to strategically develop, fund, and administer initiatives aimed at solving modern oncology problems with nanotechnology solutions.
The overarching goal of these initiatives is to discover and develop innovative nanotechnologies for application(s), ranging from discovery through to clinical translation phases, for the delivery of innovative clinically relevant technologies aimed at cancer prevention, diagnosis, control, and treatment.
This involves:
The National Institute on Minority Health and Health Disparities' (NIMHD's) mission is to lead scientific research to improve minority health and reduce health disparities.
To accomplish this, NIMHD
Quoted from NIH Guide Notice NOT-OD-01-053 — NIH Policy on Reporting Race and Ethnicity Data: Subjects in Clinical Research.
Committed to building a community of researchers dedicated to using nanotechnology to advance the fight against cancer, the Alliance is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat, and prevent cancer. The Alliance works in concert with other NCI advanced technology initiatives to provide the scientific foundation and team science that is required to transform cancer research and care.
NCORP's community-based approach builds on the scope and activities of NCI's previously supported community networks: the NCI Community Clinical Oncology Program (Community Clinical Oncology Programs, Minority-Based Clinical Oncology Programs, Research Bases), administered by the NCI Division of Cancer Prevention; and the NCI Community Cancer Centers Program (NCCCP), administered by the NCI Division of Cancer Control and Population Sciences.
From the 1980's to 2010 was comprised of the NCI Director, NCI Division Directors, and other scientists/managers (chosen by the Director); this group made scientific and management policy decisions, allocates resources, establishes grant paylines, approves grant funding plans, and reviews concepts for presentation to NCI's Board of Scientific Advisors
Grants: "The primary purpose of negotiating an award is to establish the appropriate funding level and period of performance, resolve identified problems, and agree on specialized terms and conditions of award, if needed. The degree and form of the negotiation depend on a variety of factors, such as the dollar amount and complexity of the project, nature of the problems identified, and fulfillment of new recipient requirements. The grants management specialist can usually complete negotiations and obtain needed information through correspondence with the applicant institution. However, it may become necessary for NCI staff to visit the applicant institution to address certain issues or problems.
Initial peer review recommendations, budget/programmatic modifications and determination of facilities and administrative (F&A) costs are all components of the pre-award negotiation process." (NCI OGA's "The Grants Process: The Lifecycle of a Grant")
Quoted from the NIH OAMP Acquisition Process Mapping Glossary.
See §15.406-3 of the Federal Acquisition Regulation for the documentation requirements.
For additional information visit The Network for Translational Research (NTR): Optical Imaging in Multimodal Platforms webpage.
Quoted from 21 CFR §314.3.
Quoted from the NIH OER Glossary & Acronym List.
Many of the bioengineering funding announcements and technical reports at the BECON website have migrated to the National Institute of Biomedical Imaging and Bioengineering
In particular,
Quoted from the NIH OER Glossary & Acronym List.
We publish daily, and issue a table of contents weekly.
For additional information, visit the NIH OER About the NIH Guide for Grants and Contracts webpage.
Quoted from the NIH OER Glossary & Acronym List.
For additional information, visit the NIH OER Managing Conflict of Interest in NIH Peer Review of Grants and Contracts webpage.
For additional information, see the NIH Grants Policy Statement §8.1.1 webpage.
Quoted from the NIH OER Glossary & Acronym List.
The FDA definition of Phase III clinical trials focuses primarily on a clinical investigation of drugs, vaccines, biologics, and devices. Clinical trials of experimental drugs covered in the FDA definition proceed through four phases (21 CFR Section 312.21).
For additional information regarding the FDA definitions of the different phases of clinical trials, visit the ClinicalTrials.gov website.
Quoted from the NIH OER Glossary & Acronym List.
Quoted from the NIH OER Glossary & Acronym List.
NIH requires use of the Research Performance Progress Report (RPPR) for ALL Type 5 (non-competing continuation) annual progress reports. NIH use of the PHS 2590 is restricted to progress reports for administrative extensions (Type 4s; e.g., SBIR/STTR Fast-Track Phase II application).
For additional information, visit the Non-Competing Continuation Progress Report webpage.
Quoted from §8.1.2.13 of the NIH Grants Policy Statement.
Quoted from 45 CFR §75.2.
Quoted from §300–3.1 of the Federal Travel Regulation.
See also the NIH OER Reviewer Orientation.
Quoted from the NIH OER Glossary & Acronym List.
Quoted from the NIH OER Glossary & Acronym List.